CorMedix Inc. CRMD
5.33 USD +0.03 (+0.57%)
Nov 12, 2026, 10:50 AM EST
5.15 Day range 5.49
5.10 52-week range 13.02
- YTD
- -54.17%
- 1 year
- -53.33%
- Market cap
- 423.61M
- Revenue (ttm)
- 12.26M
- EPS (ttm)
- 2.05
- Shares out
- 60.68M
- P/E ratio
- 2.60
- Forward P/E
- 17.54
- YTD return
- -54.17%
- 1-year return
- -53.33%
- Volume
- 686.80K
- Avg volume
- 1.39M
- Open
- 5.15
- Previous close
- 5.30
- Day's range
- 5.15 – 5.49
- 52-week range
- 5.10 – 13.02
- Beta
- 1.58
- Price target
- 16.25 (+204.9%)
5D -0.41 (-7.18%)
Key statistics
- Enterprise value
- 474.53M
- PEG ratio
- 0.00
- Price / sales
- 41.66
- Price / book
- 8.30
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -39.78M
- Total cash
- 46.03M
- Total debt
- 556.42K
- Return on equity
- -65.04%
- Short % of float
- 11.37%
- 50-day average
- 10.35
- 200-day average
- 6.57
Analyst view
Price target (mean) 16.25 +204.9% upside
Now 5.33
- Target (low)
- 11.00
- Target (mean)
- 16.25
- Target (high)
- 19.00
Ratings (0m) 4 4 buy · 0 hold · 0 sell
- Strong buy3
- Buy1
- Hold0
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate 0.05.
Financials — quick view
CRMD Revenue — quarterly 101.93M
CRMD Net income — quarterly 25.99M
CRMD EPS — quarterly 0.33
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 12, 2025 | Sep 1, 2025 | 0.48 | 0.57 | +0.09 | +18.75% |
| Aug 7, 2025 | Jun 1, 2025 | 0.20 | 0.28 | +0.08 | +40.00% |
| May 6, 2025 | Mar 1, 2025 | 0.25 | 0.30 | +0.05 | +20.00% |
| Mar 25, 2025 | Dec 1, 2024 | 0.17 | 0.22 | +0.05 | +29.41% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 19, 2024 | RBC Capital | main | Outperform | Outperform |
| Oct 31, 2024 | Needham | main | Buy | Buy |
| Aug 15, 2024 | RBC Capital | reit | Outperform | Outperform |
| Aug 15, 2024 | Needham | reit | Buy | Buy |
| Jul 25, 2024 | Truist Securities | main | Buy | Buy |
| Jun 19, 2024 | Needham | reit | Buy | Buy |
About CorMedix Inc.
CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- cormedix.com
News
CorMedix (CRMD) Reports Q3 Loss, Tops Revenue Estimates 
Cormedix Q3 2026 Earnings Call Transcript 
Cormedix Q3 EPS $(0.19) Misses $(0.10) Estimate, Sales $54.519M Beat $53.227M Estimate 
Cormedix Affirms FY2026 Sales Guidance of $325.000M-$345.000M vs $337.061M Est 
Cormedix Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update 
RBC Capital Maintains Outperform on Cormedix, Raises Price Target to $15 
CRMD to Acquire HRTX Assets for $223M Upfront to Expand Portfolio 
CorMedix to Acquire Heron Assets, Adding Four Products and Targeting Up to $60 Million in Savings 
Needham Maintains Buy on Cormedix, Raises Price Target to $14 
CorMedix Bolsters Hospital Pipeline via Heron Therapeutics Asset Deal
Your note
Sign in to keep a note on CRMD — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| COSTA PAULO F | Director | Purchase | May 16, 2023 | 10,000 |
| DAVID MATTHEW T M.D. | Chief Financial Officer | Stock Award(Grant) | Jan 11, 2024 | 47,934 |
| DUNTON ALAN WILLIAM | Director | Purchase | Dec 14, 2023 | 15,250 |
| KAPLAN MYRON | Director | Purchase | May 17, 2023 | 196,034 |
| LEFKOWITZ STEVEN W | Director | Conversion of Exercise of derivative security | Nov 15, 2023 | 107,650 |
| MASSON ELIZABETH | Officer | Stock Award(Grant) | Jan 11, 2024 | 45,397 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 6.03% | 3,656,294 | 30.79M | Sep 29, 2024 |
| Vanguard Group Inc | 5.06% | 3,068,677 | 25.84M | Sep 29, 2024 |
| Elliott Investment Management L.p. | 2.56% | 1,550,523 | 13.06M | Sep 29, 2024 |
| Rosalind Advisors, Inc. | 2.43% | 1,475,000 | 12.42M | Sep 29, 2024 |
| Geode Capital Management, LLC | 2.12% | 1,284,464 | 10.82M | Sep 29, 2024 |
| State Street Corporation | 2.02% | 1,225,756 | 10.32M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 2.85% | 1,731,556 | 14.58M | Sep 29, 2024 |
| iShares Russell 2000 ETF | 2.31% | 1,403,936 | 11.82M | Oct 30, 2024 |
| Vanguard Extended Market Index Fund | 1.33% | 809,912 | 6.82M | Sep 29, 2024 |
| Fidelity Small Cap Index Fund | 0.93% | 566,545 | 4.77M | Aug 30, 2024 |
| iShares Russell 2000 Growth ETF | 0.74% | 447,453 | 3.77M | Oct 30, 2024 |
| Fidelity Extended Market Index Fund | 0.50% | 302,395 | 2.55M | Oct 30, 2024 |